On Mar. 12, 2020, Innovation Pharma announced research procedures that one of the 12 Regional Biocontainment Labs (RBLs) in the U.S. will follow when testing Brilacidin, the Companyﾒs lead defensin mimetic drug candidate, against SARS-CoV-2, the coronavirus responsible for COVID-19. Testing is scheduled to begin the week of March 16.